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Introduction
Subjective tinnitus is a potentially serious neurological condition affecting 10-15%
of the general population (Bhatt et al., 2016; Tunkel et al., 2014). It is considered a
symptom that is commonly associated with hearing loss including noise-induced hearing
loss (NIHL). Subjective tinnitus is the perception of intermittent or constant “ringing”
buzzing” or “hissing” sounds in the absence of an external sound source. The incidence
of tinnitus increases during aging and is particularly prevalent in veterans due to NIHL.
Patients suffering from tinnitus often experience difficulty concentrating, sleep
deprivation, anxiety, and depression. (Hall et al. 2011), making it a debilitating condition.
Currently there are no FDA approved drugs to prevent or treat tinnitus, mainly due to a
lack of understanding of its cellular and molecular pathways.
Evidence obtained from both animal and human studies suggest that tinnitus
results from the dysfunction of several neuronal networks encompassing both auditory
and non-auditory pathways. Acoustic trauma is capable of damaging cochlear hair cells
and auditory nerve fibers that can lead to a reduction of auditory inputs. In response to
this cochlear deafferentation, the central auditory system appears to increase neural
gain to over-compensate for the reduced sensorineural input from the cochlea. Animal
studies suggests that NIHL causes hyperactivity in multiple areas of traditional and nontraditional auditory pathways (e.g., Bauer, 2004; Eggermont and Roberts, 2012;
Kaltenbach, 2011). Animals with behavioral evidence of tinnitus typically exhibit
increased spontaneous firing rates, abnormally high synchrony, and burst firing in the
dorsal and ventral subdivisions of the cochlear nucleus, as well as the inferior colliculus
(IC). This could subsequently lead to a reorganization of tonotopic maps within the
auditory cortex structures (Noble and Tyler, 2009; Vogler et al., 2011; Robertson and

Mulders, 2012; De Ridder et al., 2014; Schoisswohl et al., 2019). These findings
suggest that phantom percepts of sound arise from cochlear deafferentation, and reach
awareness only when the hyperactivity in the auditory cortex is linked to a larger
network that supports perception.
In the central nervous system, an imbalance between excitatory and inhibitory
neural activities can lead to pathological conditions such as tinnitus, schizophrenia,
autism, and Alzheimer disease. Dysfunctions of inhibitory neurons, mainly neurons that
produce and respond to gamma-aminobutyric acid (GABA), are implicated in tinnitus. In
addition, tinnitus is associated with an increase in spontaneous activity and soundevoked activity in the IC following NIHL (Richardson et al. 2012; Longenecker and
Galazyuk, 2011; Ma et al., 2006; Mulders and Robertson, 2011; Mulders et al., 2011).
Along with increased spontaneous activity, a decrease in the firing of GABA neurons is
also found (Richardson et al., 2012; Dong et al. 2010). Glutamic acid decarboxylase
(GAD) is an enzyme in the brain that catalyzes the synthesis of GABA. Decreased
mRNA expression of GAD has been shown to be linked to other related neurological
disorders such as schizophrenia, bipolar disorder, and autism (Akbarian and Huang
2006).
Besides GABA dysregulation, several molecular pathways could be involved in
tinnitus. The T-type calcium channels generate synchronized oscillatory activity in
thalamocortical circuits through calcium-dependent low-threshold spikes, which underlie
thalamic burst firing (Cheong and Shin, 2013). Among three T-type calcium channels
(CaV3.1, CaV3.2, and CaV3.3), CaV3.1 is richly expressed in thalamic neurons, and
plays a central role in the generation of thalamocortical rhythms (Cain and Snutch,

2013; Kim et al., 2001; Choi et al., 2015). Abnormal thalamocortical activity can be
attributed to the disruption of coherent oscillatory activity between thalamus and cortex
following hearing loss (Eggermont and Roberts, 2012; Eggermont and Tass, 2015). In
addition, the hyperexcitability of auditory circuits may potentially be due to other
molecular targets such as L-type calcium channels. Excess calcium influx into neurons
in auditory pathways may be attributed to the underlying mechanisms of tinnitus
(Monzani et al., 2015). Based on these previous studies, we tested a drug candidate,
tetrandrine (TET), which can block both T-type and L-type calcium channels, and found
that it was effective in treating noise-induced tinnitus in our animal model (Zuo et al.,
2017). TET is a drug approved in China for silicosis, hypertension, inflammation, and
lung cancer with a long history of good safety profile (Xie et al., 2002). Here, based on
this interesting finding. TET was further tested, along with other calcium channel
antagonists, to reveal possible molecular mechanisms of noise-induced tinnitus, and
explore new molecular targets to treat tinnitus.
Both animal and clinical studies have shown that certain drug candidates were
promising in treating tinnitus, however the molecular target and mechanisms remain
unclear, with most of them are involved in calcium signaling. Gabapentin (GAB) has
been initially found to be 50% effective in reducing psychoacoustic loudness in patients
(Richardson et al., 2012; Bauer and Brozoski 2006). GAB was designed to mimic the
neurotransmitter GABA; however it does not bind to GABA receptors. Its mechanism of
action as an antiepileptic agent likely involves its inhibition of the alpha 2-delta subunit
of voltage-gated calcium channels, which is critical for the function of L-type calcium
channels. Similarly, ethosuximide (ESM) is commonly prescribed to treat seizures and

acts as a T-type calcium channel blocker (Browne et al., 1975). Nimodipine (NMDP) is
an FDA approved L-type calcium channel blocker developed to treat high blood
pressure and has also been found to be effective in labyrinthine dysfunction (Monzani,
2015; Lassen et al., 1996; Pianese et al., 2002), dizziness (Monzani, 2015; Wu et al.,
2013), and tinnitus (Monzani et al., 2015; Davies et al., 1994; Monzani et al., 2012).
While not many recent studies have further investigated the use of NMDP in treating
tinnitus, past clinical studies have demonstrated that it might be effective (Davies et al.,
1994). Here, I examined possible effects of these drug candidates in order to determine
possible molecular signaling for tinnitus. This preliminary data will inform our next steps
in the identification of effective molecular targets for tinnitus treatment.
Materials and Methods
The procedures were completed in accordance with the Northeast Ohio Medical
University Institutional Animal Care and Use Committee. A total of 13 C57/BL/6J mice
(9 male/4 females) were included in the study and underwent behavioral training for
tinnitus detection, tinnitus induction, and treatment application and efficacy measures.
The sound-based avoidance detection (SBAD) method was used for detecting tinnitus
and testing the response to different pharmacological doses (Zuo et al., 2017).
Traumatic noise exposure was used to induce tinnitus in the mice.
Behavioral Training and Testing for Tinnitus Detection: Experimental mice were placed
in a shuttle box that was divided into two compartments. Mice were trained to cross
from side to side when sound cues were presented through MF1 speakers (“Go” trial).
Mice were trained to remain still when no sound was presented in the shuttle box (“NoGo” trial). This training was performed over 15 days. The animals were given a 15-30

minute acclimation period in the shuttle box before training began. A training session
included 100 randomly assigned trials per day, lasting approximately 30-40 minutes per
session. The Go trial sound cues were randomly played as white noise or narrow-band
noise at center frequencies of 8, 16, 20, 32, and 40 kHz, and pure tones of 8, 16, 20,
32, and 40 kHz, all of which were presented at random intensities ranging from 85-100
decibels sound pressure level (dB SPL) at 5 dB increments. To reinforce the training
sessions, the mice were shocked if they did not cross from one compartment to the
other during the Go trials. They were also shocked if they crossed sides during the NoGo trials. After the 15th training day, mice were tested for 3 days to obtain three baseline
scores. Testing procedures were repeated after noise exposure to be compared with
baseline scores. All baseline and post noise exposure testing sessions presented
randomized 90 Go trials and 30 No-Go trials with shocks enabled during the Go trials
but disabled during No-Go trials.
Tinnitus Induction: Following the successful completion of training (>/= 90% correct rate
for Go and No-Go trials), and baseline testing for 8 mice (4 males and 4 females) at
approximately 5 months of age and 5 mice (All males) at approximately 3 months of
age, the mice were re-trained for three consecutive days. They were then exposed to
traumatic noise levels over a two-day period to induce tinnitus. To protect the mice from
bilateral NIHL which would affect the performance during Go trials, one ear was
occluded with an ear plug, while the other ear was exposed to the noise. The mice were
placed in a sound booth where they were exposed to a constant 116 dB SPL broadband
noise (4-25 kHz) for two hours. Following the noise exposure, the mice were housed for
one month, and then tested to see if they have developed tinnitus. To determine if an

animal exhibited successful tinnitus induction, Chi-Squared tests using a α level of 0.05
were computed to compare no-go scores at baseline and post-exposure. A statistically
significant reduction in No-Go scores post-noise exposure compared to baseline was
considered an indication for tinnitus. If tinnitus was not present in the mice one-month
post-noise exposure, testing procedures were repeated after one month. This continued
to up to 3 months (4 total months post noise exposure).
Pharmacological testing: The drugs that were tested included TET, GAB, ESM, and
NMDP. Saline was also included to characterize the stress-related effects of animal
handling, restraint and needle injections that could affect Go and No-Go performance.
Mice that tested positive for tinnitus (n=6), underwent a series of treatment regimens
that involved various drug combinations and dosages. Appropriate drug dosages used
in this study were determined by previous preliminary work completed at this lab. Mice
were weighed the day of testing to calculate drug volume. The mice were tested 2 hours
after every intraperitoneal (IP) injection. GAB and ESM were dissolved by saline, while
TET was dissolved in dimethyl formamide. NMDP was dissolved using corn oil.
Similar to our tinnitus detection statistical analysis, efficacy of all treatment
regimens were determined by chi-squared testing with an α level of .05. If there was a
statistically significant improvement in No-Go scores post treatment compared to postnoise exposure, it would indicate successful tinnitus treatment. All statistical analyses
were computed using Jeffrey’s Amazing Statistical Package (JASP) 0.9.0.1.

Results
Chi-squared tests were first used to determine if mice were tinnitus positive by
comparing the baseline No-Go scores to post-noise exposure No-Go scores. A
significant difference (p < 0.05) of the test indicated a tinnitus positive mouse. 6 mice (4
males and 2 females) were found to be tinnitus positive for a success rate of 46% out of
the 13 mice trained. Following this analysis, the mice were tested accordingly to
determine if their No-Go scores could be improved by different drug doses and
combinations. Preliminary data indicated that TET dosages of 60 mg/kg and 30 mg/kg
were effective in treating tinnitus positive mice, while a dose of 15 mg/kg did not
significantly improve the No-Go scores (Figure 1).

Figure 1. Preliminary data on the effects on different dosages of TET in tinnitus Go (A) and No-Go (B)
scores. Dosages of 60 mg/kg, 30 mg/kg, and 15 mg/kg were used to determine the effectiveness of TET
in treating tinnitus, with the 60 and 30 mg/kg doses leading to significant differences, and the 15 mg/kg
dose having no significant difference.

Three months post noise exposure, two mice (11060-1 and 11060-2 in Figure 2)
exhibited no statistically significant change in the No-Go scores from all three baselines
(p > .31). While one mouse (11061-3) showed a significant drop of 26.67% in its No-Go
score on day 3 of testing 3 months after noise exposure (p = 0.002), this was not

enough to be considered an indication of tinnitus. In this mouse (11061-3), no
statistically significant changes were exhibited in the Go-scores from baseline in all 3month post noise exposure scores (p > 0.31), while one mouse (11060-1) had a
significant drop in its Go-score on day 3 of testing (p < 0.001). One mouse (11060-2)
had statistically significant drops in its Go-scores on days 2 and 3 of testing (p </= 0.03),
possibly due to hearing loss following noise exposure.
The 3 control mice were tested with GAB at 40 mg/kg, ESM at 300 mg/kg, and
NMDP at 30 mg/kg to observe the possible behavioral effects of these drugs. On
average, GAB did not have a significant change in the Go-scores of the mice with an
increase of 2.1%, as well as NMDP with an increase of 1.36%. ESM did cause a
significant difference in the mice with a decrease of 6.05% in the Go scores (Figure 3a).
Individually, only one of the three animals exhibited a significant change in the go
performance post ESM application (11061-1 in Figure 3a; 18.89% decrease, p=0.002).
The average change in No-Go scores for all tested drugs ranged from 3.33% to 4.43%,
all of which were not significant. No significant effects on No-Go performance were
observed from each individual animal (Figure 3b). We therefore concluded that the
tested dosages were appropriate for testing.

Figure 2. Go (A) and No-Go (B) training and testing correct rates (%) for control group. Mouse 11061-3
had a No-Go score significantly different from the baseline only on day 3 of testing post-noise trauma
after 3 months, however the remaining days were all tinnitus negative. Drug testing was carried out to
observe behavioral effects at different concentrations. TD = training day; 3M = three months post noise
exposure.

Figure 3. Averaged drug testing results of control mice (11060-1, 11060-2, and 11061-3) for correct rates
(%) ofGo (A) and No-Go (B) test trials. 3 tinnitus tests were compared with the drug tests results. There
was a significant difference in average performance of Go trials when tested with ESM (300mg/kg). While
this average change in score was significant, only one animal in the group (11061-3) yielded a significant
reduction in the Go score (*p < .05).

Group 1 included three animals that were successfully trained and tested positive
for tinnitus post noise exposure (Figure 4). One mouse (11060-3), had significant
decreases in No-Go scores on day 2 and 3 of 3-month tinnitus testing with decreases
ranging approximately 23% to 27% (p </= 0.005,). One mouse had no significant
differences on all 3 days of testing (p = 0.313, 0.161, 0.448). However, it did
subsequently exhibit hyperactive behaviors consist with other tinnitus mice. One mouse
had significant decreases in No-Go scores on day 1, 2, and 3 of testing, with decreases
ranging from approximately 23% to 37% (p </= 0.005).
On average for Group 1, the Go-Scores (Figure 5A) significantly decreased in
two of the following treatments: TET 60mg/kg (p = 0.02) and TET 60mg/kg+GAB
40mg/kg (p = 0.006) while they significantly increased in treatment with GAB at 40
mg/kg (p = 0.02). Individually, significant decreases were seen in one mouse (11061-1)
treated with TET 60mg/kg (p = 0.03) and one mouse (11060-3) treated with TET
60mg/kg+GAB 40mg/kg (p = < .001). In the averaged No-Go scores (Figure 5B), 4 of
the treatments had significant improvements, which included TET 60mg/kg (p < .001),
TET 60mg/kg+ GAB40mg/kg (p < .001), NMDP 30mg/kg (p < .001), and TET
10mg/kg+NMDP 10mg/kg (p < .001). Individually, two of the animals exhibited
significant improvements in No-Go scores for the treatment of TET 60mg/kg (11060-3, p
= 0.04; 11061-1, p < .001), TET 60mg/kg+ GAB 40mg/kg (11060-3, p = 0.01; 11061-1,
p < .001), and NMDP 30mg/kg (11060-3, p = 0.01; 11061-1, p < .001). Individually for
the TET 10mg/kg+NMDP 10mg/kg treatment, one animal had significant improvement
(11061-1, p < .001). In one of the treatments groups, ESM 300 mg/kg+GAB 40mg/kg, a
significant decrease in No-Go scores was observed (p < .001). Additionally in the No-Go

scores, no significant difference was seen in the following treatments: GAB 40mg/kg (p
= 0.382), ESM 300mg/kg (p = 0.298), ESM 300mg/kg+GAB 40mg/kg (p = 0.72), and
NMDP 10mg/kg (p = 0.382). Refer to Figures 6 and 7 for Group 1 individual and
averaged data respectively.

Figure 4. Go (A) and No-Go (B) training and testing correct rates (%) for Group 1. Two of the mice were
found to be tinnitus positive after 3 months from noise exposure, while mouse 11060-4 was not, however
it displayed erratic behavior during all three testing days and thus was included in Group 1. Drug testing
was carried out with the specified drug concentrations and combinations. TD = training day, 3 M = three
months post noise exposure.

Figure 5. Average Go (A) and No-Go (B) correct rates (%) for Group 1. 3 month tinnitus tests were
statistically compared to each individual treatment condition using chi-square tests (*p < 0.05, **p < 0.01,
***p < 0.001).

Group 2 included three animals that were successfully trained and tested positive
for tinnitus post noise exposure (Figure 6). Average Go scores for this group
significantly decreased in three of six treatment conditions: saline (p = 0.002), GAB
80mg/kg (p = 0.03), and TET 60mg/kg +GAB 80mg/kg (p < 0.001). (Figure 7A).
Average No-Go scores did not improve in any treatment condition for Group 2 (Figure
7B). Two treatment conditions (GAB 80mg/kg and GAB 40 mg/kg) yielded significant
decreases in average No-Go scores (p < .001). While there was no significant
improvement in average No-Go performance during the TET 60mg/kg+GAB 80mg/kg
treatment condition, two of three animals exhibited significant improvements(11035-1; p
= 0.02; 11036-1; p =0.002), while the third animals demonstrated significant decreases
in its performance (11035-2; p = 0.003). In the saline treatment, average No-Go
performance was not significantly affected; however one mouse (11035-2) exhibited
significant decreases in its performance (p < 0.006).

Figure 6. Go (A) and No-Go (B) training and testing correct rates (%) for Group 2. Mouse 11036-1 was
tinnitus positive 3 months after noise exposure across all three testing days (p </= 0.04), while mice
11035-1 and 11035-2 were tinnitus positive across two and one testing day/s respectively after 4 months
(p </= 0.006). While animal 11035-2 only demonstrated tinnitus-like behavior for only one out of three
testing days post noise exposure, it displayed erratic behavior during all three testing days and thus was
included in Group 2. Drug testing was carried out with the specified concentrations and combinations. TD
= training day, 3/4 M = three- or four-months post noise exposure.

Figure 7. Average Go (A) and No-Go (B) correct rates (%) for Group 2. 3 and 4-month tinnitus tests were
statistically compared to each individual treatment condition using chi-square tests (*p < 0.05, **p < 0.01,
***p < 0.001).

In summary of the drugs’ effects on tinnitus animals, average Go scores in Group
1 were significantly decreased by treatments of TET 60mg/kg and TET 60mg/kg+GAB
40mg/kg, and significantly improved by GAB 40mg/kg (Figure 5A). The average No-Go
scores in Group 1 significantly improved for the treatments of TET 60mg/kg, TET
60mg/kg+GAB 40mg/kg, NMDP 30 mg/kg, and TET 10mg/kg+NMDP 10mg/kg (Figure
5B). In Group 2, the average Go score significantly decreased with treatments of saline,
GAB 80 mg/kg, and TET 60mg/kg+GAB 80 mg/kg (Figure 7A). The average No-Go
scores for Group 2 significantly decreased with treatments of GAB 80mg/kg and GAB
40 mg/kg (Figure 7B).

Discussion
Dysregulation of calcium signaling in the central nervous system is associated
with several neurological diseases. Based on our preliminary studies, we examined if
calcium channels blockers could modify tinnitus in our noise-induced models. Our
results strongly suggested that, in contrast to our original hypothesis, T-type calcium
channels were most likely not involved in tinnitus pathology since its specific blocker,
ESM, has no effects on tinnitus even at a high dosage. Interestingly, our data did
implicate that L-type calcium channels might be involved: two blockers of L-type calcium
channels (TET and NMDP) were effective to eliminate tinnitus. However, GAB, a
blocker for high-voltage calcium channels including L-type calcium channels, could
cause worsening tinnitus. Since high-voltage calcium channels also include other
calcium channels such as P- and Q- channels. This unexpected result could be due to
complicated GAB inhibitions of these different channels in the brain. Thus, based off

these initial findings, L-type channels may be involved in noise-induced tinnitus. It is
also clear that TET alone can be an effective drug for treating tinnitus.
Both experimental groups displayed statistically significantly reduced average Go
scores when injected with saline. It is possible that the injection process caused stress
related factors that would affect SBAD performance, however it is worth noting that
there were no significant changes in No-Go scores pre and post saline injection.
Additionally, in Group 1, one mouse exhibited significant decreases in its Go scores
when treated with TET (60 mg/kg), and another exhibited significant decreases when
treated with TET (60 mg/kg)+GAB (40 mg/kg). Individually, the Go scores remained
above 80%. Regarding the aged group (Group 2), when treated with TET (60 mg/kg)
and combination therapy of TET (60 mg/kg) and GAB (80 mg/kg), there were significant
reductions in Go scores. Individually however, the decreased Go scores post treatment
were all above 80% for both therapies and there was no significant change in No-Go
scores. This is in contrast with findings from Group 1 which displayed significantly
improved averaged No-Go scores when treated with both treatment regimens. These
discrepancies between age groups needs to be investigated further, but it is possible
that age related decline of hearing, learning, and/or memory can affect behavioral data.
With our current pharmacological approach, we were not able to identify any
brain structures involved in tinnitus. It is known that the IC activity is largely associated
with the onset of tinnitus. It acts as a relay site coordinating descending and ascending
auditory signaling from cortical and subcortical sources. As such it is believed to have
an intricate system of inhibitory signaling necessary for modulation which is largely
mediated by GABAergic neurons (e.g. Ito et al., 2009). Dysfunction of GABA neurons is

believed to be associated with increases in spontaneous activity that could lead to the
perception of phantom sounds (Richardson et al. 2012; Longenecker and Galazyuk,
2011; Ma et al., 2006; Mulders and Robertson, 2011; Mulders et al., 201). In the IC,
high voltage calcium channel currents are contributed to primarily by high threshold
voltage-activated calcium channel types, including L-, N, and P-types, while low voltage
threshold activated calcium channels such as T-type calcium channels have lower
expression and do not seem to significantly contribute to the action potentials and
neuronal firing of the IC (N’Gouemo and Morad, 2003). Thus, when using ESM to block
the activity of the T-type calcium channels, the low contribution of T-type calcium
channels in IC activity did not cause any significant changes, while blocking the L-type
calcium channels had a significant effect due to its strong contribution to the overall
calcium currents of the IC. In the future, I plan to use molecular techniques to directly
quantify gene expressions of these channels in the ICs of mice with or without tinnitus,
which would lead to a clearer picture on how these channels are involved in tinnitus.
There are several limitations in this study. First, our findings were obtained from
a small number of mice positive for tinnitus due to the low-rate of noise-induced tinnitus.
Due to a small sample size, we opted to include all tinnitus positive mice (including
those that did not statically indicate tinnitus, but had behavioral signs of tinnitus) for
analysis and they did consistently support the use of TET in treating tinnitus. However,
a lower dose of TET should be explored in order to avoid possible behavioral changes.
In the future, more strict criteria should be followed when testing animals to provide
reliable and consistent results. The discrepancies of findings between our two
experimental group highlights potential age-related effects such as hearing sensitivity,

memory and learning that could affect our behavioral data. Therefore, when using this
experimental mouse model, we advise testing animals under the age of one year.
Additionally, improving methods for noise-induced tinnitus or establishing new methods
to induce tinnitus could increase the likelihood of mice developing tinnitus so that a
larger sample size can be used. Other alternatives such as salicylate induced tinnitus
may lead to more animals with temporal tinnitus, however it is not an accurate
representation of most forms of tinnitus experienced by humans, as noise trauma and
aging are believed to be more associated with the development and maintenance of
subjective tinnitus in the general population.
Besides increasing our sample size to obtain stronger data, we will expand our
studies to map new molecular targets for treating tinnitus and use different blockers and
agonists of L-type calcium channels to confirm if L-type calcium channels are involved
in tinnitus. Once a narrower list of molecular targets has been made, single molecular
fluorescence in situ hybridization (smFISH) will be performed in order to analyze the
gene expression of these certain targets in the brain.
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